Florida Hospital Study of BioSeal CVC™ Powder Selected for Podium
Presentation at the 2009 Association for Vascular Access Conference
Published Friday, August 28, 2009
by Patti Norris
FOR IMMEDIATE RELEASE
CONTACT: Andrew McFall
Director of Marketing and Communications
(800) 722-7559 Extension 117
Email: andrew.mcfall@biolife.com
Biolife is pleased to announce that a study of BioSeal CVC™ Powder, formerly PRO QR Powder, has been selected for a
podium presentation at the Association for Vascular Access (AVA) Annual Conference in Las Vegas, September 15-17,
2009. The study abstract entitled, “The Science of a “Seal” for Peripherally Inserted Central Catheter (PICC) Line
Management: an alternative hemostatic agent that keeps sites dry and intact” is one of four selected for presentation out
of more than 50 abstracts submitted.
This clinical study was conducted by the Vascular Access Services (VAS) Team of Florida Hospital in Orlando. The VAS
team, a leader in patient care and vascular access innovations, assessed the ability of BioSeal CVC™ Powder to
achieve hemostasis for PICC line insertions and to eliminate the 48-hour dressing change. Lauren Blough, Clinical
Supervisor of the VAS Team at Florida Hospital, and Principal Investigator of the study, will give the oral presentation
during the conference, held at the Riviera Hotel and Casino, between 8 a.m. – 9 a.m. on Thursday, September 17.
BioSeal CVC™ Powder, a mixture of a hydrophilic polymer and potassium ferrate, is a topical powder that forms an
occlusive seal to protect an access site and keep it dry and intact. Results of the study at Florida Hospital demonstrated
an overwhelming user-preference for BioSeal CVC™ Powder relative to the gauze control standard-of-care. Outcomes of
the study were as follows:
Biolife President Sam Shake says of the opportunity, “We are pleased that our friends at Florida Hospital were chosen to
present this study. The VAS team of Florida Hospital is first rate and this study gives Biolife the platform for broadening
the awareness of our products in the vascular access community. The study highlights the benefits of BioSeal CVC™,
both from a patient care and a cost savings perspective.”
In addition to the podium presentation, the study will be featured in a Poster Showcase at the AVA Conference. Posters
are open for viewing each day of the conference from 7 am to 5 pm.
Presentation at the 2009 Association for Vascular Access Conference
Published Friday, August 28, 2009
by Patti Norris
FOR IMMEDIATE RELEASE
CONTACT: Andrew McFall
Director of Marketing and Communications
(800) 722-7559 Extension 117
Email: andrew.mcfall@biolife.com
Biolife is pleased to announce that a study of BioSeal CVC™ Powder, formerly PRO QR Powder, has been selected for a
podium presentation at the Association for Vascular Access (AVA) Annual Conference in Las Vegas, September 15-17,
2009. The study abstract entitled, “The Science of a “Seal” for Peripherally Inserted Central Catheter (PICC) Line
Management: an alternative hemostatic agent that keeps sites dry and intact” is one of four selected for presentation out
of more than 50 abstracts submitted.
This clinical study was conducted by the Vascular Access Services (VAS) Team of Florida Hospital in Orlando. The VAS
team, a leader in patient care and vascular access innovations, assessed the ability of BioSeal CVC™ Powder to
achieve hemostasis for PICC line insertions and to eliminate the 48-hour dressing change. Lauren Blough, Clinical
Supervisor of the VAS Team at Florida Hospital, and Principal Investigator of the study, will give the oral presentation
during the conference, held at the Riviera Hotel and Casino, between 8 a.m. – 9 a.m. on Thursday, September 17.
BioSeal CVC™ Powder, a mixture of a hydrophilic polymer and potassium ferrate, is a topical powder that forms an
occlusive seal to protect an access site and keep it dry and intact. Results of the study at Florida Hospital demonstrated
an overwhelming user-preference for BioSeal CVC™ Powder relative to the gauze control standard-of-care. Outcomes of
the study were as follows:
- 98% of respondents considered BioSeal CVC™ Powder effective for controlling PICC line access site bleeding
- No site infections or other complications were reported
- Extended post-trial use of the product demonstrated a ~40% reduction in Catheter-related Bloodstream Infections
(CRBSIs) according to a post-hoc review of documentation - Florida Hospital has eliminated the 48-hour dressing change and added BioSeal CVC™ Powder to PICC line
insertion protocol. The initial dressing change is now performed at 7 days.
Biolife President Sam Shake says of the opportunity, “We are pleased that our friends at Florida Hospital were chosen to
present this study. The VAS team of Florida Hospital is first rate and this study gives Biolife the platform for broadening
the awareness of our products in the vascular access community. The study highlights the benefits of BioSeal CVC™,
both from a patient care and a cost savings perspective.”
In addition to the podium presentation, the study will be featured in a Poster Showcase at the AVA Conference. Posters
are open for viewing each day of the conference from 7 am to 5 pm.
| Empowering The World With A Revolutionary Powder |